Virginia’s Two Milligram Hemp Cap Has Been in Force for a Month, and the Court Let It Stand

Since August 15, 2026, a product may be sold in Virginia as a hemp product only if it contains no more than 0.3 percent total tetrahydrocannabinol and no more than two milligrams of total THC per package. The earlier alternative, which allowed a package above two milligrams when it carried at least 25 times as much cannabidiol, is no longer in the statute. The Virginia Cannabis Control Authority states that the enacted law includes no sell-through or grace period for existing inventory.

The legal question drew a federal challenge and the challenge failed at the preliminary stage. What the statute did not do is change the pharmacology of anything a patient was taking. A tincture that helped someone sleep did not become less useful on August 15. It became unsellable in Virginia, which is a different fact, and one that pushes people toward substitutes chosen without clinical input.

Virginia had one of the more permissive intoxicating hemp markets on the East Coast because of the cannabidiol ratio allowance. Removing it in a single step, with no sell-through window, moved a large share of full-spectrum oral products off shelves at once. People who had settled on a stable dose lost that product with no transition plan.

Substitution after a market change is where the avoidable harm sits. A patient who was taking a low, predictable oral dose and cannot find it again tends to reach for whatever is still available, which in practice means a more concentrated product, an inhaled product, a marijuana dispensary product under a different legal framework, or an out-of-state order of unknown provenance. Each of those changes onset, duration, and impairment profile.

The operative text sits in the Code of Virginia. Section 4.1-600 defines a hemp product as one that, when offered for retail sale, contains a total tetrahydrocannabinol concentration of no greater than 0.3 percent and contains no more than two milligrams of total tetrahydrocannabinol per package. Section 3.2-4112, in the version effective August 15, 2026 until July 1, 2027, points to that definition and carries the amendment history for the 2026 Special Session I, Chapter 1 change.

The prior version of section 3.2-4112, effective until August 15, 2026, contained the alternative that is now gone. It permitted a package with either no more than two milligrams of total THC or an amount of cannabidiol no less than 25 times greater than the amount of total THC. That second branch is what allowed high-cannabidiol full-spectrum products, and some products marketed as hemp THC edibles, to sit on ordinary retail shelves in Virginia.

Total THC in Virginia is a calculated figure, not the delta-9 number alone. It accounts for tetrahydrocannabinolic acid converting to THC, which is why a product marketed on its low delta-9 content can still exceed the cap.

A group of Virginia hemp businesses sued in Northern Virginia Hemp and Agriculture, LLC v. Spanberger, No. 7:26-cv-00615, in the U.S. District Court for the Western District of Virginia. The case was filed July 31, 2026 and assigned to District Judge Robert S. Ballou.

On August 14, 2026, the day before the cap took effect, the court entered a memorandum opinion and an order denying the plaintiffs’ motion for a temporary restraining order and their motion for a preliminary injunction. The limit took effect on schedule the next morning.

A denial of preliminary relief is a ruling about what happens while a case proceeds, not a final judgment on the merits. The docket shows the case still open. Readers should hold both facts at once: the law is in force today, and the litigation over it has not ended. Neither fact says anything about whether a particular product helped a particular patient.

Retail hemp oversight shifted from the Virginia Department of Agriculture and Consumer Services to the Virginia Cannabis Control Authority. The Authority now handles inspections, enforcement, and the assessment of violations and penalties tied to the packaging, labeling, and testing of edible hemp products, and it can issue notices of violation, cease and desist orders, and civil penalties.

Retailers selling regulated hemp products register per location, with a separate application and a non-refundable application fee of one thousand dollars for each site. That cost falls hardest on single-location shops, which is part of why the retail map changed quickly rather than gradually.

Virginia’s medical cannabis program is a separate legal track and was not narrowed by this change. Registered patients buy from pharmaceutical processors under a different chapter of the code, with different possession and potency rules. Virginia retail cannabis sales are scheduled to begin July 1, 2027, which is also the date the current version of section 3.2-4112 expires.

The predictable pattern after a shelf change is silent substitution. A patient does not call the office to report that a product is gone. They buy the nearest available thing and keep going, and the clinician finds out months later, often after a new symptom or an unexplained change in another medication’s effect.

The specific swaps worth asking about are an oral product traded for an inhaled one, a two milligram package traded for a marijuana dispensary product, a labeled product traded for an unlabeled or mail-order one, and a cannabidiol-dominant product traded for something with a far lower cannabidiol to THC ratio. The last one matters because the repealed provision selected for high-cannabidiol formulations, so the products most likely to disappear were the ones with the most cannabidiol in them.

There is also a group of Virginia families who had built a routine around a high-cannabidiol oral preparation for a child with a seizure disorder. Those cases belong with a neurologist, not with a retail substitution, and pharmaceutical cannabidiol has a trial evidence base that hemp shelf products do not.

Patients read national hemp headlines and reasonably assume they apply locally. In Virginia right now they do not, and the reason is worth stating plainly.

At the federal level, section 781 of Public Law 119-37, signed November 12, 2025, was scheduled to take effect November 12, 2026. H.R. 6500, the continuing appropriations act signed September 2, 2026, moved most of those provisions to December 11, 2026, while leaving the exclusion for cannabinoids that a cannabis plant cannot naturally produce on the original November 12, 2026 schedule.

Virginia’s two milligram per package cap is state law that already took effect on August 15, 2026, and it is stricter than the federal threshold that is being argued about. A federal delay of a federal restriction does not restore a product that Virginia law independently bars from retail sale. A Virginia patient who hears that Congress pushed a hemp deadline to December should not expect their old product to reappear.

As a legal description this rests on the strongest sources available: the Code of Virginia itself, the Cannabis Control Authority’s own published requirements, and a federal court docket. Those establish what the rule is, when it started, and what the court did. On those points the page is not summarizing anyone’s interpretation.

As clinical evidence it carries nothing at all, and the distinction should stay visible to readers. No study supports two milligrams as a therapeutic ceiling, a safety threshold, or a dose with any particular effect. The number is a regulatory line drawn through a market, and it would be a mistake to read it as a dosing recommendation in either direction.

Reporting around the August deadline leaned heavily on business estimates of how much inventory would be pulled. Those figures came from affected sellers and describe a commercial loss, not a measured statewide count of products, patients, or purchases. They should not be converted into a prevalence claim.

One widely read account placed the case in the Eastern District of Virginia. The docket shows the Western District, Roanoke Division. Small errors like that propagate quickly in policy coverage, which is a reason to read the docket rather than the summary of it.

It is also too early to know where displaced demand went. Whether Virginia buyers moved to the medical program, to marijuana obtained outside a regulated channel, to mail order, or away from cannabinoids entirely is an empirical question nobody has answered yet.

Nothing here shows that products removed from Virginia shelves were unsafe, poorly made, or ineffective. The statute sorts products by cannabinoid content, not by manufacturing quality, label accuracy, or contamination, and a compliant product is not by that fact a better one.

Nothing here shows that the cap reduces harm. There is no published measurement yet of Virginia poison center calls, pediatric exposures, emergency visits, or impaired driving before and after August 15. Those are the outcomes that would tell anyone whether this worked, and they have not been reported.

Virginia is one of several states that spent 2026 redrawing the boundary between hemp and cannabis at the state level while the federal definition was in motion. The states are not moving in the same direction or on the same timetable, and a patient who crosses a state line during a road trip can carry a legal product into an illegal one without any change in what is in the bottle.

The pattern that repeats across these fights is that the regulated medical channel is left intact or expanded while the unregulated retail channel is compressed. That is defensible public health policy. It also assumes that displaced buyers will enter the medical channel, and that assumption deserves testing rather than confidence, because registration cost, clinician access, and stigma all sit in the way.

The part of this that concerns me is not the number. Two milligrams per package is arbitrary, but most regulatory thresholds are, and I can work with a defined line. What concerns me is the absence of a sell-through period, because that turns a policy change into a same-week supply interruption for people who were doing fine.

When a patient loses a product abruptly, the substitution happens within days and it happens without me. By the time I hear about it, the person has often moved from a measured oral dose to an inhaled product or to something with no label at all, and we have lost the one thing that made their regimen manageable, which was knowing what was in it.

So the practical instruction to Virginia colleagues is narrow. Ask every patient who used hemp products what they are taking this month and what they were taking in July. If the answer changed, treat it as a medication change, because that is what it is.

Virginia’s two milligram per package hemp cap has been in force since August 15, 2026, the cannabidiol ratio alternative is repealed, there was no sell-through period, and a federal judge denied both emergency and preliminary relief on August 14. The clinical task is no longer anticipating the change. It is documenting what each patient switched to and whether that substitute is appropriate for them.

Carry forward three things: the limit is current law and not a proposal, the court’s refusal to block it settled the near term rather than the merits, and a federal deadline moving to December does nothing to a stricter Virginia rule already in effect. Do not carry forward any sense that two milligrams describes a safe dose or that products above it were shown to be harmful.